347 related articles for article (PubMed ID: 32524338)
21. Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product.
Lee KH; Lee J; Bae JS; Kim YJ; Kang HA; Kim SH; Lee SJ; Lim KJ; Lee JW; Jung SK; Chang SJ
MAbs; 2018 Apr; 10(3):380-396. PubMed ID: 29469653
[TBL] [Abstract][Full Text] [Related]
22. A Developer's Perspective on Clinical Evidence and Benefits for Rituximab Biosimilar Uptake, with a Focus on CT-P10.
Choi D; Lee S; Kim S; Yoon S
Clin Drug Investig; 2022 Apr; 42(4):285-300. PubMed ID: 35325438
[TBL] [Abstract][Full Text] [Related]
23. Real-world experience of rituximab biosimilar GP2013 in rheumatoid arthritis patients naïve to or switched from reference rituximab.
Łosińska K; Korkosz M; Pripp AH; Haugeberg G
Rheumatol Int; 2023 May; 43(5):881-888. PubMed ID: 36922417
[TBL] [Abstract][Full Text] [Related]
24. Safety of switching between rituximab biosimilars in onco-hematology.
Urru SAM; Spila Alegiani S; Guella A; Traversa G; Campomori A
Sci Rep; 2021 Mar; 11(1):5956. PubMed ID: 33727667
[TBL] [Abstract][Full Text] [Related]
25. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
Lee S; Lee H; Kim E
BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
[TBL] [Abstract][Full Text] [Related]
26. The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non-interventional post-authorization safety study in Europe.
Bishton M; Marshall S; Harchowal J; Salles G; Golfier C; Tucci A; Fernández AR; Sanchez Blanco JJ; Bocchia M; Kim S; Lee YN; Zinzani PL
Hematol Oncol; 2022 Aug; 40(3):370-380. PubMed ID: 35168291
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study.
Toosi R; Mahmoudi H; Balighi K; Teimourpour A; Alaeen H; Shaghaghi M; Abedini R; Daneshpazhooh M
J Dermatolog Treat; 2021 Feb; 32(1):33-40. PubMed ID: 31074302
[No Abstract] [Full Text] [Related]
28. Immunogenicity of Rituximab biosimilar GP2013 in chronic inflammatory rheumatic disorders in daily clinical practice.
Avouac J; Cougnaud Murail R; Goulvestre C; Dumas S; Molto A; Miceli-Richard C; Conort O; Batteux F; Allanore Y
Semin Arthritis Rheum; 2022 Feb; 52():151951. PubMed ID: 35038642
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.
Belleudi V; Trotta F; Addis A; Ingrasciotta Y; Ientile V; Tari M; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Trifirò G;
Drug Saf; 2019 Dec; 42(12):1437-1447. PubMed ID: 31228010
[TBL] [Abstract][Full Text] [Related]
30. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.
De Vita S; Quartuccio L; Isola M; Mazzaro C; Scaini P; Lenzi M; Campanini M; Naclerio C; Tavoni A; Pietrogrande M; Ferri C; Mascia MT; Masolini P; Zabotti A; Maset M; Roccatello D; Zignego AL; Pioltelli P; Gabrielli A; Filippini D; Perrella O; Migliaresi S; Galli M; Bombardieri S; Monti G
Arthritis Rheum; 2012 Mar; 64(3):843-53. PubMed ID: 22147661
[TBL] [Abstract][Full Text] [Related]
31. Brief Report: Safety and Immunogenicity of Rituximab Biosimilar GP 2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis.
Tony HP; Krüger K; Cohen SB; Schulze-Koops H; Kivitz AJ; Jeka S; Vereckei E; Cen L; Kring L; Kollins D
Arthritis Care Res (Hoboken); 2019 Jan; 71(1):88-94. PubMed ID: 30295429
[TBL] [Abstract][Full Text] [Related]
32. Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.
Ogura M; Coiffier B; Kwon HC; Yoon SW
Future Oncol; 2017 May; 13(15s):45-53. PubMed ID: 28482699
[TBL] [Abstract][Full Text] [Related]
33. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: A Bayesian network meta-analysis
.
Bae SC; Lee YH
Int J Clin Pharmacol Ther; 2019 Apr; 57(4):188-196. PubMed ID: 30574867
[TBL] [Abstract][Full Text] [Related]
34. Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study.
Buske C; Jurczak W; Sancho JM; Zhavrid E; Kim JS; Hernández-Rivas JÁ; Prokharau A; Vasilica M; Nagarkar R; Kwak L; Kim WS; Lee S; Kim S; Ahn K; Ogura M
Blood Adv; 2021 Sep; 5(17):3354-3361. PubMed ID: 34477816
[TBL] [Abstract][Full Text] [Related]
35. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial.
Smolen JS; Cohen SB; Tony HP; Scheinberg M; Kivitz A; Balanescu A; Gomez-Reino J; Cen L; Poetzl J; Shisha T; Kollins D
Rheumatology (Oxford); 2021 Jan; 60(1):256-262. PubMed ID: 32699904
[TBL] [Abstract][Full Text] [Related]
37. A non-interventional, post-marketing surveillance study evaluating the safety and effectiveness of biosimilar rituximab (CT-P10) during routine clinical practice in the Republic of Korea.
Jo JC; Jeon Y; Kim D; Yang DH; Lee WS; Choi YS; Yi JH; Yoon DH; Kong JH; Choe JY; Kim S; Ahn K; Park T; Ju H; Kwon S; Cho SG
Expert Opin Biol Ther; 2023; 23(8):737-747. PubMed ID: 36757373
[TBL] [Abstract][Full Text] [Related]
38. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature.
Ferri C; Cacoub P; Mazzaro C; Roccatello D; Scaini P; Sebastiani M; Tavoni A; Zignego AL; De Vita S
Autoimmun Rev; 2011 Nov; 11(1):48-55. PubMed ID: 21821153
[TBL] [Abstract][Full Text] [Related]
39. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis.
Yoo DH; Suh CH; Shim SC; Jeka S; Cons-Molina FF; Hrycaj P; Wiland P; Lee EY; Medina-Rodriguez FG; Shesternya P; Radominski S; Stanislav M; Kovalenko V; Sheen DH; Myasoutova L; Lim MJ; Choe JY; Lee SJ; Lee SY; Kwon TS; Park W
Ann Rheum Dis; 2017 Mar; 76(3):566-570. PubMed ID: 27624791
[TBL] [Abstract][Full Text] [Related]
40. Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study.
Quartuccio L; Zuliani F; Corazza L; Scaini P; Zani R; Lenzi M; Tavoni A; Sebastiani M; Baldovino S; Urraro T; Saccardo F; Sbreglia C; Mazzaro C; Pioltelli P; Fraticelli P; Filippini D; Gabrielli A; Perrella O; Scarpato S; Roccatello D; Zignego AL; Ferri C; Bombardieri S; Pietrogrande M; Monti G; Galli M; De Vita S
J Autoimmun; 2015 Sep; 63():88-93. PubMed ID: 26255249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
